EUVIMEDEUVIMED entdecken
Crossref

Survival, Toxicity, and Economic Outcomes of Osimertinib Versus Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Epidermal Growth Factor Receptor–Mutant Non–Small Cell Lung Cancer

Po-Huang Chen iD, Hong-Jie Jhou iD, Wei-Cheng Chang iD, Hsin-Yu Chen iD, Li-Ting Kao iD, Tina Yi-Jin Hsieh, Ren-Hua Ye, Shiue-Wei Lai, Jia-Hong Chen, Ching-Liang Ho iD, Cho-Hao Lee iD

JCO Oncology Practice · 06.05.2026

DOI: 10.1200/op-25-01390 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Practice, online erschienen am 06.05.2026. Verfasst von Po-Huang Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiw…. Die Arbeit nennt 30 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Direct real-world comparisons between osimertinib and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are lacking, particularly regarding the comparative effectiveness, safety, and economic implications of different treatment sequencing strategies. METHODS We emulated a target trial using the TriNetX database to study adults with newly diagnosed metastatic EGFR-mutant non–small cell lung cancer (NSCLC). After 1:1 propensity score matching, 777 patients in the first-line osimertinib arm were compared with 777 patients in the second-generation TKI arm. The primary outcome was overall survival (OS), with secondary outcomes including health care utilization and toxicity. RESULTS First-line osimertinib demonstrated significantly longer median OS compared with second-generation TKIs (53.4 v 33.2 months; hazard ratio [HR], 0.618). Although sequential therapy (second-generation TKI followed by osimertinib) achieved similar OS, it was associated with significantly higher toxicity. Patients with brain metastases derived greater benefit from osimertinib (HR, 0.563). Osimertinib also significantly reduced rates of hospitalization, intensive care unit admission, and severe infections, generating substantial health care savings ($5.73 million per 1,000 patients) despite higher drug costs. CONCLUSION First-line osimertinib provides prolonged OS and meaningful economic benefits over second-generation TKIs. Given the higher toxicity burden of sequential therapy despite similar survival outcomes, our findings support the implementation of first-line osimertinib to optimize patient experience and reduce health care utilization in metastatic EGFR-mutant NSCLC.

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan.
  • Department of Oncology, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan.
  • Neurological Institute, Changhua Christian Hospital, Changhua, Taiwan.
  • Department of Ophthalmology, Taoyuan Hospital, Ministry of Health and Welfare, Taiwan.
  • Department of Family Medicine, Chi Mei Medical Center, Tainan, Taiwan.
  • Graduate Institute of Life Sciences, National Defense Medical University, Taipei, Taiwan.

ORCID-Profile: Po-Huang Chen, Hong-Jie Jhou, Wei-Cheng Chang, Hsin-Yu Chen, Li-Ting Kao, Ching-Liang Ho, Cho-Hao Lee

Zitieren

APA

Chen, P. H., Jhou, H. J., Chang, W. C., Chen, H. Y., Kao, L. T., Hsieh, T. Y., Ye, R. H., Lai, S. W., Chen, J. H., Ho, C. L., & Lee, C. H. (2026). Survival, Toxicity, and Economic Outcomes of Osimertinib Versus Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Epidermal Growth Factor Receptor–Mutant Non–Small Cell Lung Cancer. JCO Oncology Practice. https://doi.org/10.1200/op-25-01390

Vancouver

Chen PH, Jhou HJ, Chang WC, Chen HY, Kao LT, Hsieh TY, et al. Survival, Toxicity, and Economic Outcomes of Osimertinib Versus Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Epidermal Growth Factor Receptor–Mutant Non–Small Cell Lung Cancer. JCO Oncology Practice. 2026. doi:10.1200/op-25-01390

BibTeX
@article{Chen2026,
  author = {Chen, Po-Huang and Jhou, Hong-Jie and Chang, Wei-Cheng and Chen, Hsin-Yu and Kao, Li-Ting and Hsieh, Tina Yi-Jin and Ye, Ren-Hua and Lai, Shiue-Wei and Chen, Jia-Hong and Ho, Ching-Liang and Lee, Cho-Hao},
  title = {Survival, Toxicity, and Economic Outcomes of Osimertinib Versus Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Epidermal Growth Factor Receptor–Mutant Non–Small Cell Lung Cancer},
  journal = {JCO Oncology Practice},
  year = {2026},
  doi = {10.1200/op-25-01390}
}
Kostenlos starten →